^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MESP1 (Mesoderm Posterior BHLH Transcription Factor 1)

    i
    Other names: MESP1, Mesoderm Posterior BHLH Transcription Factor 1, BHLHc5, Mesoderm Posterior Basic Helix-Loop-Helix Transcription Factor 1, Class C Basic Helix-Loop-Helix Protein 5, Mesoderm Posterior Protein 1, MGC10676, Mesoderm Posterior 1 Homolog (Mouse), Mesoderm Posterior 1 Homolog, BHLHC5
    Associations

    News

    Trials
    1m
    USP7 Stabilizes MESP1 To Promote the Malignant Progression of Non-Small Cell Lung Cancer. (PubMed, Appl Biochem Biotechnol)
    Overexpression of MESP1 attenuated the inhibitory effects of USP7 silencing on NSCLC cell proliferation and M2 macrophage polarization and also mitigated the promoting effects of USP7 knockdown on apoptosis and the induction of features associated with ferroptosis. USP7 stabilized MESP1 to promote the malignant progression of NSCLC. The findings highlight the potential of targeting the USP7-MESP1 axis as a novel therapeutic strategy for NSCLC.
    Journal
    |
    CD163 (CD163 Molecule) • USP7 (Ubiquitin Specific Peptidase 7) • MESP1 (Mesoderm Posterior BHLH Transcription Factor 1)
    8ms
    Demethylzeylasteral suppresses the expression of MESP1 by reducing H3K18la level to inhibit the malignant behaviors of pancreatic cancer. (PubMed, Cell Death Discov)
    Importantly, MESP1 has also been connected to various cancer metabolism pathways, such as MAPK, PI3K-AKT, and carbon metabolism. This research is groundbreaking in demonstrating that DML impedes the malignant behavior of PC cells by downregulating H3K18la levels and diminishing the expression of the oncogene MESP1.
    Journal
    |
    MESP1 (Mesoderm Posterior BHLH Transcription Factor 1)
    over2years
    MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. (PubMed, Biochem Biophys Res Commun)
    Furthermore, siRNA interference of MESP1 expression combined with 5-FU-treatment of HCC cells significantly enhanced the G1-S phase block and apoptosis. MESP1 showed an aberrant high expression in HCC and was associated with poor clinical outcomes; therefore, MESP1 may be a potential target for the diagnosis and treatment of HCC.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • GSK3B (Glycogen Synthase Kinase 3 Beta) • SNAI1 (Snail Family Transcriptional Repressor 1) • MESP1 (Mesoderm Posterior BHLH Transcription Factor 1)
    |
    BCL2 expression • MYC expression